Applications have opened for a national accelerator programme supporting data-driven health innovation. KQ Labs, led by the Francis Crick Institute and Medicines Discovery Catapult (MDC), is an annual five-month programme for early-stage companies building science-backed, scalable solutions in AI-driven drug discovery, digital health, and precision medicine. … Read More
The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has announced the first cohort of drug discovery projects to receive its Collaborative Discovery Programme (CDP) funding. The £3 ($3.9) million programme, funded by LifeArc, will support six early-stage novel antimicrobial projects over two years to accelerate new treatments for lung infections… Read More
ERS Genomics and not-for-profit Medicines Discovery Catapult (MDC) have signed a non-exclusive commercial-use CRISPR license agreement. The partnership hopes to combine ERS’s CRISPR/Cas9 patent portfolio with MDC’s expertise and technology. As part of the deal, MDC and its partners will benefit from access to ERS’ CRISPR/Cas9 portfolio – the foundational… Read More
Professor Chris Molloy, CEO of Medicines Discovery Catapult (MDC), writes about the state of the UK’s drug discovery sector, exploring economic challenges and what is needed to support the country’s rich life sciences talent. We should all be proud of and inspired by the UK life sciences sector’s rich… Read More
A national total-body positron emission tomography (PET) imaging platform for drug discovery is launching in the UK next year. It is hoped that the National PET Imaging Platform (NPIP) will transform medical research and industrialise cutting-edge technology, enhancing the quality and speed of drug discovery. Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with… Read More
